Sarepta faces FDA scrutiny over Elevidys as analysts downgrade stock and warn of long-term debt risks amid market uncertainty ...

On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.

Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $106.75, a high estimate of $202.00, and a low estimate of $75.00.

Sarepta Therapeutics’ stock has dropped precipitously as questions swirl around the safety of its gene therapies. Meanwhile, the Duchenne patient community fears losing access to Elevidys while the ...

Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...

Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price. Read why I am reiterating my bullish rating on ARWR stock.

Over the past 3 months, 6 analysts have published their opinion on Sarepta Therapeutics (NASDAQ:SRPT) stock. These analysts are typically employed by large Wall Street banks and tasked with ...

Sarepta stock crashed Friday on reports the FDA will ask the biotech company to stop shipments of its approved gene therapy, ...

is the subject of a research note from Lazard Capital Markets Wednesday in which analyst Bill Tanner summarizes feedback from some doctors in the Duchenne muscular ...

Shares of Sarepta shot up, again, on Monday as investors responded warmly to Oppenheimer’s bullish views on a possible accelerated approval for its Duchenne muscular dystrophy drug eteplirsen.

Over the past 3 months, 6 analysts have published their opinion on Sarepta Therapeutics (NASDAQ:SRPT) stock. These analysts are typically employed by large Wall Street banks and tasked with ...